March Biosciences

March Biosciences, founded in Houston, Texas, is a clinical-stage company dedicated to advancing cell therapy solutions for hematological cancers. Their core mission is to transform patient care by developing innovative CAR-T cell strategies that target the most challenging blood cancers. The company's flagship product, MB-105, is a CD5 CAR T-cell therapy currently in clinical development for treating T-cell lymphoma.

Key figures associated with March Biosciences include leading researchers and clinicians in the field of cell therapy. The company has garnered attention for its promising pipeline and has made significant strides in clinical trials, positioning itself as a pioneer in CAR-T cell therapy. March Biosciences' impact is evident in its potential to revolutionize treatment options for patients with hematological cancers, offering new hope where traditional therapies have failed.